Connect with us

Published

on

The United States Food and Drug Administration (FDA) has approved suzetrigine, a non-opioid painkiller, for short-term pain management. This approval marks the first time in over two decades that a new pain relief mechanism has been introduced. Suzetrigine, which selectively targets sodium channels on pain-sensing neurons, has been developed as an alternative to opioids, which have been linked to addiction and overdose crises. The drug is expected to provide pain relief similar to opioids but without the associated risks of dependency, sedation, or overdose.

Targeting Sodium Channels for Pain Relief

According to research presented at a major anesthesiology conference last year, suzetrigine, now branded as Journavx, works by blocking the NaV1.8 sodium channel subtype, which plays a key role in transmitting pain signals. Unlike traditional sodium channel-blocking drugs like lidocaine, which act on all nine subtypes indiscriminately, suzetrigine is designed to target pain-sensing neurons specifically. This selectivity reduces side effects and allows the drug to be taken orally rather than requiring local application.

Clinical Trials and Effectiveness

In clinical trials, more than 80% of participants reported effective pain relief after surgery or injury. Trials on individuals undergoing procedures such as bunion removal and tummy tucks showed that suzetrigine provided pain relief comparable to opioid-based regimens, with fewer side effects. Paul White, an anesthesiologist at Cedars-Sinai Medical Center, stated to Nature, that increasing non-opioid options could significantly reduce opioid dependency.

Challenges and Future Prospects

Suzetrigine has been priced at $15.50 per pill, a cost that remains higher than generic opioids but is considered cost-effective given the expenses associated with opioid addiction treatment. While its effectiveness in chronic pain conditions remains uncertain, pharmaceutical companies are advancing similar drugs targeting sodium channels, aiming to expand non-opioid pain relief options.

Continue Reading

Science

ISRO Says Gaganyaan Mission Is 90 Percent Complete, Aiming for 2027 Launch

Published

on

By

ISRO has completed 90 percent of the Gaganyaan mission’s development. With three test flights ahead, India is set to join the elite group of nations capable of sending humans to space by 2027, marking a landmark step in its space exploration journey.

Continue Reading

Science

Saturn’s Moon Titan Breaks One of Chemistry’s Oldest Rules, NASA Study Reveals

Published

on

By

Saturn’s moon Titan has shocked scientists by breaking a key chemistry rule. NASA and Chalmers University researchers found that polar and nonpolar molecules, usually immiscible, can mix under Titan’s extreme cold. The discovery deepens our understanding of prebiotic chemistry and could reveal how life’s building blocks form in frigid extraterrestrial environmen…

Continue Reading

Science

Scientists Construct 5-Micron Engine Generating Effective Heat of 13 Million Degrees Celsius Without Burning

Published

on

By

A team of scientists has created a microscopic engine made from a 5-micrometre glass bead suspended in an electric field. By applying oscillating voltages, the bead moves as if it’s in an environment of 13 million°C, even though it remains cool. The study reveals bizarre thermodynamic effects at tiny scales, offering clues to how natural molecular “machines” wo…

Continue Reading

Trending